
(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Danish warship sunk by famed British admiral discovered after 225 years - 2
Italian authorities detain civilian rescue ship, German NGO says - 3
Al-Sharaa denies he called for 80% of Syrians to return from Germany - 4
Artemis 2 astronauts see Earth in the rear-view mirror | Space photo of the day for April 3, 2026 - 5
Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
Clones of Stumpy, Washington D.C.'s beloved cherry blossom tree, have flowered for the first time
NASA Perseverance rover sees megaripples on Mars | Space photo of the day for Jan. 7, 2026.
In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
It Shouldn’t Be Here: Rescuers Race to Save Whale Stranded in Rare Spot
Electric Vehicles for Eco-Accommodating Driving
'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
NASA releases stunning new images captured by the Artemis II moon mission, including 'Earthset' and a solar eclipse from space
Early diagnosis leads King Charles to scale back cancer treatment in the new year
Nine in 10 German industrial firms expect Iran war to hit business













